SURVEY DETAILS

TARGET POPULATION

For this Network Survey, GLG surveyed 90 global pharma and biotech CDMO decision makers from US, EU and APAC.

What will you learn from this survey?

  • Respondents evaluated key players in large molecule CDMOs such as Lonza, Catalent, Samsung Biologics, and Wuxi Biologics, and trending players in small molecule CDMOs such as Siegfried, Syngene, Wuxi Apptec, and Piramal.
  • The survey also investigated the current spending trends on CDMOs and the outlook for service demand by product types (including small molecule, biologics, vaccines, peptides, and CGT), views on key CDMOs’ service quality and operational stability.
  • Lastly, the research looked at whether or not the evaluation criteria for selecting CDMO partners have changed considering the macro environment (including geopolitical risk, the introduction of the Inflation Reduction Act (IRA) and the recent legislation, global economic downturn and increasing competitive dynamics).

Examples of findings:

  • Peptides are among the most outsourced products, over four-in-ten experts declared to be outsourcing around 75% to 100% of their production to CDMOs, followed by biologics drug substance with one-third outsourcing the same proportion.
  • Six-in-ten respondents declared that CDMOs’ quality has increased over the last 5 years, however, close to one-in-five reported that such quality has significantly increased.
  • Around three-in-five experts anticipate that prices will become somewhat higher in the following 1 to 5 years, however, nearly one-in-five respondents foresee significantly higher pricing for the next 3 to 5 years.

DELIVERABLES

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Guido Dietrich, Former VP of Global Quality Assurance at Merck, Lonza and GSKl.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • In-depth PowerPoint report of survey findings presented by the Council Member via webcast (optional).

SAMPLE QUESTIONS

  • In your opinion, how has CDMO service quality changed over the last 5 years at the industry level?
  • How do you view the available capacity for CDMO services today?
  • Over the next years, how do you foresee the total usage of the below CDMO(s) to change?
  • On a scale of 1 to 10 (1 being not at all likely, 10 being extremely likely), how likely would you outsource the following type of project to the following CDMOs?
  • How does the availability of commercial production capacity influence your choice of pre-GMP (pre-clinical)-stage vendor for CDMO services?
  • Do you apply the same criteria for outsourcing of Biologics and Small Molecule drugs?
  • What would be the key reasons to switch a CDMO provider?
  • How would you rate the following CDMO provider’s performance in each of the below categories?

ACCESS

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.

 

 

Thank you for contacting GLG, someone will respond to your inquiry as soon as possible.